The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Celastrol Suppresses Angiogenesis-Mediated Tumor Growth through Inhibition of AKT/Mammalian Target of Rapamycin Pathway
Open accessAbstract
Understanding the molecular basis and target of traditional medicine is critical for drug development. Celastrol, derived from Trypterygium wilfordii Hook F. (“Thunder of God Vine”), a traditional Chinese medicine plant, has been assigned anticancer activities, but its mechanism is not well understood. Here, we investigated whether Celastrol could inhibit angiogenesis-mediated tumor growth and, if so, through what mechanism. When given s.c. to mice bearing human prostate cancer (PC-3 cell) xenografts, Celastrol (2 mg/kg/d) significantly reduced the volume and the weight of solid tumors and decreased tumor angiogenesis. We found that this agent inhibited vascular endothelial growth factor (VEGF)–induced proliferation, migration, invasion, and capillary-like structure formation by primary cultured human umbilical vascular endothelial cells (HUVEC) in a dose-dependent manner. Furthermore, Celastrol abrogated VEGF-induced sprouting of the vessels from aortic rings and inhibited vascular formation in the Matrigel plug assay in vivo. To understand the molecular mechanism of these activities, we next examined the signaling pathways in treated HUVECs and PC-3 tumor cells. Celastrol suppressed the VEGF-induced activation of AKT, mammalian target of rapamycin (mTOR), and ribosomal protein S6 kinase (P70S6K). Additionally, we found that Celastrol inhibited the proliferation of prostate cancer cells and induced apoptosis, and these effects correlated with the extent of inhibition of AKT/mTOR/P70S6K signaling. Taken together, our results suggest that Celastrol targets the AKT/mTOR/P70S6K pathway, which leads to suppression of tumor growth and angiogenesis. Cancer Res; 70(5); 1951–9
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Biology of Cancer: Metabolic Reprogramming Fuels Cell Growth and Proliferation
DeBerardinis, R. J., Lum, J. J., Hatzivassiliou, G., & Thompson, C. B. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2007.10.002 · Cited by 4,088
Allison, A. C., Cacabelos, R., Lombardi, V. R. M., Álvarez, X. A., & Vigo, C. (2001) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(01)00192-0 · Cited by 376
Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer
Wolpin, B. M., Hezel, A. F., Abrams, T., Blaszkowsky, L. S., Meyerhardt, J. A., Chan, J. A., Enzinger, P. C., Allen, B., Clark, J. W., Ryan, D. P., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.9514 · Cited by 297
Vascular endothelial growth factor contributes to prostate cancer-mediated osteoblastic activity
Kitagawa, Y., Dai, J., Zhang, J., Keller, J. M., Nor, J., Yao, Z., & Keller, E. T. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1809 · Cited by 101
Self-citation
Cited by
Targeting the STAT3 signaling pathway in cancer: Role of synthetic and natural inhibitors
Siveen, K. S., Sikka, S., Surana, R., Dai, X., Zhang, J., Kumar, A. P., Tan, B. K. H., Sethi, G., & Bishayee, A. (2014) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2013.12.005 · Cited by 634
Self-citationChallenges to effective cancer control in China, India, and Russia
Goss, P. E., Strasser-Weippl, K., Lee-Bychkovsky, B. L., Fan, L., Li, J., Chavarri-Guerra, Y., Liedke, P. E. R., Pramesh, C. S., Badovinac-Crnjevic, T., Sheikine, Y., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70029-4 · Cited by 496
Kannaiyan, R., Shanmugam, M. K., & Sethi, G. (2011) · Cancer Letters · doi:10.1016/j.canlet.2010.10.025 · Cited by 346
Terpenoids: natural products for cancer therapy
Huang, M., Lu, J.-J., Huang, M.-Q., Bao, J.-L., Chen, X.-P., & Wang, Y.-T. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.727395 · Cited by 333
Targeting apoptosis pathways in cancer by Chinese medicine
Li-Weber, M. (2013) · Cancer Letters · doi:10.1016/j.canlet.2010.07.015 · Cited by 318
Metadata
- Authors
- Pang, X., Yi, Z., Zhang, J., Lu, B., Sung, B., Qu, W., Aggarwal, B. B., & Liu, M.
- Venue
- Cancer Research
- Published
- 2010-02-28
- Volume
- 70
- Issue
- 5
- Pages
- 1951-1959
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2028939316
- Cited by
- 216
- References
- 4
- FWCI
- 51.13
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Celastrol Suppresses Angiogenesis-Mediated Tumor Growth through Inhibition of AKT/Mammalian Target of Rapamycin Pathway. https://app.cochat.ai/papers/10.1158/0008-5472.can-09-3201
- The paper
- Pang, X., Yi, Z., Zhang, J., Lu, B., Sung, B., Qu, W., Aggarwal, B. B., & Liu, M. (2010). Celastrol Suppresses Angiogenesis-Mediated Tumor Growth through Inhibition of AKT/Mammalian Target of Rapamycin Pathway. Cancer Research. https://doi.org/10.1158/0008-5472.can-09-3201
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.